A detailed history of Price T Rowe Associates Inc transactions in Siga Technologies Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 31,715 shares of SIGA stock, worth $190,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,715
Previous 30,437 4.2%
Holding current value
$190,290
Previous $232,000 7.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.74 - $11.97 $8,613 - $15,297
1,278 Added 4.2%
31,715 $215,000
Q2 2024

Aug 14, 2024

BUY
$6.32 - $10.46 $7,944 - $13,148
1,257 Added 4.31%
30,437 $232,000
Q1 2024

May 15, 2024

BUY
$4.51 - $8.92 $10,003 - $19,784
2,218 Added 8.23%
29,180 $250,000
Q4 2023

Feb 14, 2024

BUY
$4.82 - $6.25 $2,988 - $3,875
620 Added 2.35%
26,962 $151,000
Q3 2023

Nov 14, 2023

BUY
$4.32 - $5.77 $4,091 - $5,464
947 Added 3.73%
26,342 $139,000
Q2 2023

Aug 14, 2023

BUY
$5.0 - $6.31 $1,985 - $2,505
397 Added 1.59%
25,395 $129,000
Q1 2023

May 15, 2023

BUY
$5.23 - $8.42 $3,844 - $6,188
735 Added 3.03%
24,998 $144,000
Q4 2022

Feb 14, 2023

BUY
$7.29 - $10.14 $5,511 - $7,665
756 Added 3.22%
24,263 $179,000
Q3 2022

Nov 14, 2022

BUY
$10.02 - $26.15 $27,284 - $71,206
2,723 Added 13.1%
23,507 $243,000
Q2 2022

Aug 15, 2022

SELL
$6.5 - $13.68 $63,648 - $133,954
-9,792 Reduced 32.03%
20,784 $241,000
Q1 2022

May 16, 2022

BUY
$5.96 - $7.61 $103,704 - $132,414
17,400 Added 132.06%
30,576 $217,000
Q4 2021

Feb 14, 2022

SELL
$6.96 - $9.26 $6,876 - $9,148
-988 Reduced 6.98%
13,176 $99,000
Q2 2021

Aug 16, 2021

BUY
$6.1 - $7.58 $3,507 - $4,358
575 Added 4.23%
14,164 $89,000
Q1 2021

May 17, 2021

BUY
$6.3 - $7.71 $85,610 - $104,771
13,589 New
13,589 $88,000

Others Institutions Holding SIGA

About SIGA TECHNOLOGIES INC


  • Ticker SIGA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 73,024,096
  • Market Cap $438M
  • Description
  • SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...
More about SIGA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.